The latest price target for LeMaitre Vascular (NASDAQ:LMAT) was reported by Barrington Research on February 26, 2026. The analyst firm set a price target for $105.00 expecting LMAT to fall to within 12 months (a possible -4.08% downside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for LeMaitre Vascular (NASDAQ:LMAT) was provided by Barrington Research, and LeMaitre Vascular maintained their outperform rating.

The last upgrade for LeMaitre Vascular Inc happened on August 6, 2025 when Barrington Research raised their price target to $95. Barrington Research previously had a market perform for LeMaitre Vascular Inc.

The last downgrade for LeMaitre Vascular Inc happened on February 28, 2025 when Barrington Research changed their price target from N/A to N/A for LeMaitre Vascular Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LeMaitre Vascular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LeMaitre Vascular was filed on February 26, 2026 so you should expect the next rating to be made available sometime around February 26, 2027.

While ratings are subjective and will change, the latest LeMaitre Vascular (LMAT) rating was a maintained with a price target of $95.00 to $105.00. The current price LeMaitre Vascular (LMAT) is trading at is $109.47, which is out of the analyst’s predicted range.